Influence of B Cell Depletion By Monoclonal Anti CD20 Antibodies in Systemic Sclerosis: Results of a Randomized Placebo Controlled Trial

被引：0
作者：
Ben Said-Bouyeri, Samira [1 ]
Meijs, Jessica [1 ]
Marsan, Nina Ajmone [2 ]
Schouffoer, Anne A. [1 ]
Ninaber, Maarten K. [3 ]
Scherer, Hans Ulrich [4 ]
Bonte-Mineur, Femke [5 ]
Huizinga, T. W. J. [1 ]
de Vries-Bouwstra, Jeska K. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Cardiol, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Pulmonol, Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[5] Maasstad Hosp, Rotterdam, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
836
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ofatumumab (HuMax-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial
    Ostergaard, M.
    Baslund, B.
    Rigby, W.
    Rojkovich, B.
    Jorgensen, C.
    Petersen, J.
    Kastberg, H.
    Dawes, P.
    Sierakowski, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 124 - 124
  • [22] Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
    Okroj, Marcin
    Osterborg, Anders
    Blom, Anna M.
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 632 - 639
  • [23] B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis
    Calabresi, Peter A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) : 280 - 282
  • [24] A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
    Esther S. Frisch
    Roxanne Pretzsch
    Martin S. Weber
    Neurotherapeutics, 2021, 18 : 1602 - 1622
  • [25] A rapid and effective depletion of B cells using CD19 and CD20 monoclonal antibodies coupled to high density microparticles (HDM).
    Houde, H
    Schmittling, R
    Lu, T
    Ritz, J
    Monroy, R
    BONE MARROW TRANSPLANTATION, 1999, 23 : S161 - S161
  • [26] Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
    Perez-Callejo, D.
    Gonzalez-Rincon, J.
    Sanchez, A.
    Provencio, M.
    Sanchez-Beato, M.
    CANCER TREATMENT REVIEWS, 2015, 41 (08) : 680 - 689
  • [27] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Finn Sellebjerg
    Morten Blinkenberg
    Per Soelberg Sorensen
    CNS Drugs, 2020, 34 : 269 - 280
  • [28] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Sellebjerg, Finn
    Blinkenberg, Morten
    Sorensen, Per Soelberg
    CNS DRUGS, 2020, 34 (03) : 269 - 280
  • [29] Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
    Davis, TA
    Czerwinski, DK
    Levy, R
    CLINICAL CANCER RESEARCH, 1999, 5 (03) : 611 - 615
  • [30] Intravascular lymphoma treated with anti CD20 monoclonal antibodies.: Report of one case
    Alfaro, J
    Espinoza, A
    Manríquez, M
    Moyano, L
    González, N
    Larrondo, M
    Figueroa, G
    REVISTA MEDICA DE CHILE, 2004, 132 (11) : 1403 - 1406
12345